Candriam S.C.A. Caribou Biosciences, Inc. Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRBU
# of Institutions
135Shares Held
52.6MCall Options Held
148KPut Options Held
70.7K-
Black Rock Inc. New York, NY6.95MShares$12.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.62MShares$8.31 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC4.57MShares$8.23 Million0.0% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA4.31MShares$7.75 Million0.49% of portfolio
-
Kynam Capital Management, LP Princeton, NJ2.36MShares$4.24 Million0.38% of portfolio
About Caribou Biosciences, Inc.
- Ticker CRBU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,840,800
- Market Cap $110M
- Description
- Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...